Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Molecular Profile||Indication/Tumor Type||Response Type||Relevant Treatment Approaches||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|HRAS G13R||thyroid gland cancer||sensitive||MK2206||Preclinical - Cell culture||Actionable||In a preclinical study, MK2206 inhibited AKT activation, proliferation, and growth of thyroid cancer cell lines with PI3K/AKT pathway alterations in culture, including an anaplastic thyroid cancer cell line harboring HRAS G13R (PMID: 21289267).||21289267|
|HRAS G13R||renal pelvis transitional cell carcinoma||predicted - sensitive||Tipifarnib||Case Reports/Case Series||Actionable||In a Phase II trial, Zarnestra (tipifarnib) demonstrated manageable toxicity profile, resulted in an objective response rate of 33.3% (5/15) in patients with transitional cell carcinoma harboring HRAS mutations, a patient with renal pelvis transitional cell carcinoma harboring HRAS G13R achieved a partial response (PMID: 32636318; NCT02535650).||32636318|
|HRAS G13R||head and neck squamous cell carcinoma||predicted - sensitive||Tipifarnib||Preclinical - Pdx||Actionable||In a preclinical study, a head and neck squamous cell carcinoma patient-derived xenograft (PDX) model harboring HRAS G13R was sensitive to treatment with Zarnestra (tipifarnib), demonstrating inhibition of tumor growth, decreased cell proliferation, and reduced Erk activity (PMID: 32727882).||32727882|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|